The National Cancer Institute (NCI) has awarded Mayo Clinic an $11.5 million grant to fund a Specialized Program of Research Excellence (SPORE) in hepatobiliary cancer through August 2023.
Headed by principal investigators Mark A. McNiven, Ph.D., and Lewis R. Roberts, M.B., Ch.B., Ph.D., the goal of the Mayo Clinic Hepatobiliary SPORE is to make discoveries and translate them into the clinic for the benefit of individuals diagnosed with or at risk of liver cancer and bile duct cancer.
SPORE grants are designed to promote interdisciplinary research and help basic research findings move quickly from the laboratory to patient care. To earn these competitive grants, institutions must demonstrate a high degree of collaboration between top scientists and clinicians and show excellence in translational research projects. The Mayo Clinic Hepatobiliary SPORE brings together researchers with expertise in basic, translational and clinical science from all three Mayo Clinic campuses in Arizona, Florida and Minnesota.
This is the first time the NCI has funded a SPORE focused on hepatobiliary cancer, which can be particularly deadly. Less than 18 percent of patients diagnosed with liver or bile duct cancer survive five years or more. The NCI estimates there will be 42,220 new cases of these cancers in 2018, representing 2.4 percent of all new cancer cases, but an estimated 30,200 patients diagnosed with these cancers will die in 2018, representing 5 percent of all cancer deaths. A CDC report released in July 2018 indicated that death rates from liver cancer increased by 43 percent for men and 40 percent for women between 2000 and 2016.
The Hepatobiliary SPORE is comprised of four research projects and three scientific cores designed to consolidate and facilitate the expertise required for effective liver and bile duct cancer research.
The four research projects in the Hepatobiliary SPORE are:
The Mayo Clinic Hepatobiliary SPORE will also develop hepatobiliary cancer investigators through two programs:
"These projects and programs are designed to identify and develop new scientists in liver and bile duct cancer," says Dr. McNiven. "I'm hoping this SPORE will help encourage people all around the country and the world to continue to come to Mayo for their liver cancer care."
Three scientific cores will support SPORE research projects and career development programs:
The Hepatobiliary SPORE is part of the Mayo Clinic Cancer Center's Gastrointestinal Cancer Program, which aims to develop and pursue innovative science that will lead to practice-changing outcomes that reduce the incidence of gastrointestinal cancers and increase survival.
The Mayo Clinic Cancer Center has five other current NCI SPORE grants in breast cancer, lymphoma (shared with the University of Iowa), multiple myeloma, ovarian cancer and pancreatic cancer. Mayo Clinic also has a brain cancer SPORE operating under a no-cost extension.
Tags: cancer, Chen Wang, Edward Leof, gastrointestinal cancer, Gregory Gores, John Copland III, Lewis Roberts, liver cancer, Mark McNiven, Mark Truty, Mayo Clinic Cancer Center, Michael Torbenson, Mitesh Borad, News, Richard Vile, SPORE, Sumithra Mandrekar, Tushar Patel